Metoprolol is listed in drug reference databases as capable of causing muscle cramps, joint aches, and general musculoskeletal discomfort, and some people who take it do report these symptoms. But the picture from controlled research is surprisingly murky. A large systematic review found that most side effects people attribute to beta-blockers, including metoprolol, occur at similar rates in patients taking a placebo, suggesting the drug itself may not be to blame in many cases. Understanding why some individuals genuinely develop muscle or joint pain while others are likely experiencing something else entirely requires looking at how metoprolol behaves in the body, who metabolizes it differently, and how powerfully expectation alone can produce real physical symptoms.
What the Clinical Literature Actually Reports
Beta-blockers as a class have been linked to a range of musculoskeletal complaints. A case report published in a pediatric journal summarized the clinical picture plainly: these drugs “have been associated with muscle cramps, muscular weakness, generalized fatigue, myopathy, lactic acidosis, and elevation of creatinine kinase levels.”1PubMed Central. Mitochondrial Disorder Aggravated by Metoprolol That list sounds alarming, but context matters. These associations come largely from case reports and post-marketing surveillance rather than large controlled trials, and the frequency of genuine musculoskeletal harm appears low in the broader population taking metoprolol for hypertension or heart conditions.
Fatigue is by far the most commonly reported complaint among metoprolol users, and some people interpret the heavy, sluggish feeling in their limbs as muscle pain when it is really a consequence of reduced cardiac output and lower exercise capacity. Metoprolol slows the heart rate and blunts the adrenaline-driven surge that normally kicks in during physical effort. When your muscles get less blood flow during activity than they are accustomed to, the sensation can feel like weakness, aching, or soreness even without any direct damage to the muscle tissue itself.
Why Metoprolol Reaches Muscle Tissue More Easily Than Some Other Beta-Blockers
Not all beta-blockers are created equal when it comes to penetrating tissues beyond the heart. Metoprolol is lipophilic, meaning it dissolves easily in fat and crosses cell membranes readily. Research comparing different beta-blockers found that metoprolol has a brain-to-blood concentration ratio of roughly 14 to 1, similar to propranolol at 17 to 1, while the water-soluble atenolol sits at about 0.1 to 1.2American Heart Journal. The clinical importance of cardioselectivity and lipophilicity in beta blockers That high tissue penetration means metoprolol does not just act on the heart. It gets into skeletal muscle, the brain, and other organs far more than a hydrophilic drug like atenolol would.
This lipophilicity is relevant because beta-2 receptors, which are found in skeletal muscle and smooth muscle tissue, can be affected when enough drug accumulates in those tissues. Metoprolol is considered cardioselective, preferentially blocking beta-1 receptors on the heart. But selectivity is dose-dependent. At higher doses, metoprolol increasingly blocks beta-2 receptors as well, and its lipophilic nature helps it reach those receptors in muscle tissue efficiently. This is one plausible biological pathway through which muscle-related side effects could emerge, particularly at higher doses or in people who metabolize the drug slowly.
Metoprolol and Exercise Performance
If you have noticed that your muscles tire faster or ache more during physical activity since starting metoprolol, there is a physiological explanation that does not involve direct muscle damage. Research on beta-blockade and exercise metabolism found that these drugs alter the way muscles use their stored energy. Specifically, beta-blockade decreases the rate of glycogen breakdown during dynamic exercise at high workloads, driven by changes in the enzyme systems that regulate glycogen use.3American Journal of Physiology. Effects of beta-blockade on glycogen metabolism in human subjects during exercise Glycogen is the fuel your muscles burn during sustained effort. When the drug slows down access to that fuel, your muscles fatigue earlier and recover more slowly.
This metabolic interference helps explain a common experience: people on metoprolol feel that their workouts are harder, their muscles get sore more easily, and they recover more slowly. They may describe this as the drug “causing” muscle pain, and in a sense it does, but through reduced exercise capacity rather than any toxic effect on the muscle fibers themselves. The distinction matters because this type of discomfort often improves as the body adapts to the drug over weeks, and it can be managed by adjusting exercise intensity rather than discontinuing the medication.
The Nocebo Effect Is a Bigger Factor Than Most People Realize
Here is where the story gets genuinely interesting. A systematic review that compared side effects reported in beta-blocker trials against those reported in the placebo arms of the same trials found something striking: the majority of adverse effects people blame on beta-blockers in heart failure are not actually caused by the drugs. They arise from the underlying disease, from other coincident problems, or from the nocebo effect, where the expectation of side effects produces real symptoms.4PubMed Central. Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: Recommendations for patient information
The nocebo phenomenon is not imaginary pain. It produces measurable physiological changes. When you read a drug’s side-effect list and see “muscle pain,” your brain’s pain processing systems can actually amplify normal bodily sensations into something that feels like a genuine side effect. The review’s authors recommended changing how side-effect information is communicated to patients, precisely because the standard practice of listing every possible complaint inadvertently creates many of those complaints.
This does not mean you should dismiss muscle or joint pain while on metoprolol. But it does mean that stopping the drug to “test” whether it is the cause can be misleading. If you expect to feel better after stopping, the nocebo effect works in reverse, producing improvement through expectation alone. A more reliable approach is to discuss a structured drug holiday or dose reduction with your prescriber, ideally in a way that minimizes expectation bias.
Joint Pain Specifically
Joint pain is a distinct complaint from muscle pain, and the evidence here is even less supportive of a direct metoprolol effect. A study using data from the Osteoarthritis Initiative, which followed patients with knee osteoarthritis for four years, compared pain scores across five classes of blood pressure medication. Beta-blocker users consistently had among the lowest pain scores. In men at baseline, beta-blocker users reported an average pain score of 1.3 compared to 3.3 for calcium channel blocker users. In women, the gap was 2.0 versus 3.8.5PubMed Central. The effects of different antihypertensive drugs on pain and joint space width of knee osteoarthritis – A comparative study with data from Osteoarthritis Initiative If anything, beta-blockers were associated with less joint pain in this population, not more.
A separate analysis of over 1,100 participants with symptomatic knee osteoarthritis looked specifically at whether beta-blocker use affected pain, widespread joint symptoms, or the need for strong pain medication. The results were flatly negative. Beta-blocker users had virtually identical WOMAC pain scores to other antihypertensive users, with a within-person difference of just 0.1 points. The proportion of participants reporting widespread joint pain was nearly the same between groups, about 40% in both. Use of strong prescription pain medication was also comparable.6Osteoarthritis and Cartilage / Elsevier. Lack of evidence that beta blocker use reduces knee pain, areas of joint pain, or analgesic use among individuals with symptomatic knee osteoarthritis
So while metoprolol might plausibly cause muscle-related symptoms through the metabolic and tissue-penetration pathways described above, the case for it causing joint pain is weak. People with joint pain who also happen to take metoprolol are likely experiencing symptoms driven by osteoarthritis, aging, deconditioning, or another medication rather than the beta-blocker itself.
Why Some People Are Hit Harder Than Others
One of the most underappreciated factors in metoprolol side effects is genetic variation in how the drug is processed. Metoprolol is broken down primarily by the liver enzyme CYP2D6, and the gene coding for this enzyme is one of the most variable in the human genome. A clinical pharmacogenetics guideline found high-quality evidence that people who are CYP2D6 poor metabolizers experience significantly greater drug exposure and a more pronounced drop in heart rate compared to normal metabolizers.7Wiley Online Library / Clinical Pharmacology & Therapeutics. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy
Roughly 5 to 10 percent of people of European ancestry are CYP2D6 poor metabolizers, with rates varying across ethnic groups. For these individuals, a standard 50-milligram dose of metoprolol can produce blood levels several times higher than intended. Higher blood levels mean more drug reaching skeletal muscle tissue, more beta-2 receptor blockade, and a greater chance of musculoskeletal symptoms like cramping, weakness, and exercise intolerance. If you have started metoprolol and find the side effects unusually severe or dose-disproportionate, pharmacogenomic testing for CYP2D6 status can be genuinely useful. A poor-metabolizer result might prompt your doctor to switch to a different beta-blocker or use a much lower dose.
Drug interactions compound this problem. Several common medications inhibit CYP2D6 and can effectively turn a normal metabolizer into a poor metabolizer while taking metoprolol. Certain antidepressants, particularly fluoxetine and paroxetine, are potent CYP2D6 inhibitors. If you started one of these medications around the same time as metoprolol, or if one was added later, the combination could raise metoprolol levels enough to trigger side effects that were not present on the beta-blocker alone.
Sorting Out the Real Cause of Your Symptoms
If you are experiencing muscle or joint pain while taking metoprolol, the honest answer is that several explanations are more likely than a direct drug effect, but the drug cannot be ruled out entirely. A practical approach involves considering timing, dose, and competing explanations.
- Timing: Did the pain begin within the first few weeks of starting metoprolol or increasing the dose? A temporal link at least makes a drug effect plausible. Pain that started months later with no dose change is less likely to be metoprolol-related.
- Dose and metabolism: Higher doses increase the chance of musculoskeletal effects. If you are on a moderate or high dose and also take a CYP2D6 inhibitor, your effective exposure may be much higher than the prescribed dose suggests.
- Activity level: If the pain is mostly during or after exercise, it may reflect the metabolic changes discussed earlier rather than a toxic muscle effect. Adjusting workout intensity before blaming the drug is worth trying.
- Other medications: Statins are the single most common cause of muscle pain among people taking cardiovascular medications. If you take both a statin and metoprolol, the statin is the far more likely culprit. The same goes for certain other drugs like fibrates and some antibiotics.
- Underlying conditions: Heart failure, peripheral artery disease, and diabetes can all cause muscle symptoms that predate or worsen independently of beta-blocker therapy.
Your doctor can check a creatine kinase level to look for actual muscle breakdown, which would suggest a true myopathy rather than subjective pain. If the level is normal, direct muscle damage from the drug is unlikely. A structured trial of switching to a water-soluble beta-blocker like atenolol, which penetrates muscle tissue far less, can also be informative. If your symptoms improve on a hydrophilic beta-blocker at an equivalent dose, that points toward metoprolol’s lipophilicity as the issue.
Metoprolol Succinate Versus Metoprolol Tartrate
Metoprolol comes in two salt forms that are dispensed for different reasons. Metoprolol tartrate (Lopressor) is immediate-release and typically taken twice a day. Metoprolol succinate (Toprol-XL) is extended-release and taken once daily. The succinate form produces a smoother, lower peak blood level because the drug is released gradually. The tartrate form, by contrast, creates a sharper spike in blood levels after each dose, which can mean transient periods of higher tissue exposure.
For someone experiencing muscle symptoms that seem to come and go throughout the day, especially if they correlate with the timing of doses, switching from tartrate to succinate can sometimes help. The flatter drug level curve means less time spent at the peak concentrations where beta-2 blockade and tissue penetration are highest. This is a practical conversation to have with a prescriber, particularly if the muscle symptoms are bothersome but the medication is otherwise working well for blood pressure or heart rate control.
When Children and Young Adults Are Affected
Metoprolol is occasionally prescribed to younger patients for conditions like supraventricular tachycardia or migraine prevention. The case report describing metoprolol’s effects in a pediatric patient with an underlying mitochondrial disorder is a useful cautionary example: the drug worsened pre-existing mitochondrial muscle dysfunction in a way that was clinically significant.1PubMed Central. Mitochondrial Disorder Aggravated by Metoprolol Mitochondrial disorders are rare, but they illustrate a principle that applies more broadly. Beta-blockers can unmask or worsen musculoskeletal problems that are subclinical before the drug is introduced. If a young person develops unexplained muscle weakness, elevated creatine kinase, or exercise intolerance on metoprolol, the possibility of an underlying metabolic or mitochondrial condition is worth exploring rather than simply attributing everything to the drug and moving on.
In otherwise healthy younger patients, the exercise-related effects described earlier tend to be the dominant complaint. Younger people are generally more physically active and notice the reduction in peak exercise capacity more acutely than older, more sedentary patients. This can feel like a new onset of muscle pain when it is really a ceiling on performance that was not previously noticeable.